Sangamo Therapeutics sangamo.com


Public list: BIO 2016 (619) Pharma Startups (4743) Cancer Therapeutics (1148) Rare Diseases (230)

Sangamo Therapeutics is focused on translating science into genomic medicines with the potential to transform patients' lives using the company's platform technologies in genome editing, gene therapy, gene regulation, and cell therapy.

Sangamo Therapeutics is focused on translating science into genomic medicines with the potential to transform patients' lives using the company's platform technologies in genome editing, gene therapy, gene regulation, and cell therapy.

Company (IPO / Went public)

Phone: 510-970-6000

Fax:

Point Richmond Tech Center II
501 Canal Boulevard Suite A100
Richmond, 94804
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Sangamo Therapeutics $16.2M Jan 12, 2001
See all 60 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Sangamo Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
The Stephens GroupVenture CapitalLittle Rock, Arkansas, United StatesUnattributed VC - II
AAC Capital PartnersAsset/Investment ManagementAmsterdam, NetherlandsPIPE
LODH Private Equity PartnersAsset/Investment ManagementSwitzerlandUnattributed VC - II, Unattributed VC
Palladin GroupUnattributed VC - II
JAFCO Life Science InvestmentVenture CapitalTokyo, JapanUnattributed VC - II, Unattributed VC
See all 5 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors
See all 60 competitors